Tonghua Golden-Horse reappoints auditor, announces financial guarantees

Tonghua Golden-Horse Pharmaceutical Industry (SZSE:000766) announced the re-appointment of Beijing Dehao International Certified Public Accountants (Special General Partnership) as its auditor for the 2025 fiscal year. The firm will cover financial and internal control audits, with a fee of 1.7 million yuan. This decision was approved by the board on November 12, 2025, and awaits shareholder approval on November 28, 2025.

The company also approved two significant guarantee provisions. First, a guarantee of up to 160 million yuan for its wholly-owned subsidiaries, Harbin Saint-Thai Biological Pharmaceutical Co., Ltd. (up to 80 million yuan) and Chengdu Yongkang Pharmaceutical Co., Ltd. (up to 80 million yuan), both for the 2025 fiscal year. Harbin Saint-Thai Biological Pharmaceutical has a debt-to-asset ratio exceeding 70%.

Second, the company’s wholly-owned subsidiaries, Chengdu Yongkang Pharmaceutical Co., Ltd. and Harbin Saint-Thai Biological Pharmaceutical Co., Ltd., will provide a joint guarantee for the parent company's financing and loans, up to a total of 350 million yuan. This includes 150 million yuan with China Construction Bank and 200 million yuan with Jilin Bank, all approved by the board on November 12, 2025. These guarantees are subject to shareholder approval on November 28, 2025.